Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...
Biogen Inc. ( NASDAQ: BIIB) Stifel 2025 Virtual CNS Forum Conference March 18, 2025 10:15 AM ET Great. Good morning, everybody. Happy to be moderating my annual panel where Priya has to listen to me ...
Clinical Trials Arena on MSN6d
INOVIO’s Covid-19 dMAb maintains in-vivo detection in 100% participantsResults saw all 24 healthy volunteers who made it to the 72-week mark still had effective levels of dMAb in their systems.
Other candidates include anti-BDCA2 antibody litifilimab in phase 3 for SLE and phase 2 for cutaneous lupus erythematosus (CLE) – also partnered with UCB – and felzartamab, an anti-CD38 ...
INOVIO’s DNA-encoded monoclonal antibodies (dMAbs) have been able to maintain biologically relevant levels in 100% of Covid-19 in a Phase I proof-of-concept trial. Out of the 24 healthy ...
At close: March 14 at 4:00:00 PM EDT Loading Chart for IMAB ...
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und . Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TC BIOPHARM HOLDINGS PLC ADR finden Sie auf ...
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und . Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BLACK DIAMOND THERAPEUTICS INC finden Sie auf ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback